A clinical-stage biotechnology company focused on developing immune-modulating therapies for autoimmune and neurological diseases. Its lead asset, MIS416, has been studied as a treatment for progressive multiple sclerosis and works by targeting innate immune pathways. Investors have followed the com...
No congressional trades have been disclosed for Innate Immunotherapeutics Ltd (INIMF) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.